Welcome to our dedicated page for Bridgebio Pharma SEC filings (Ticker: BBIO), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The BridgeBio Pharma, Inc. (NASDAQ: BBIO) SEC filings page on Stock Titan provides access to the company’s regulatory disclosures as filed with the U.S. Securities and Exchange Commission. BridgeBio is a biopharmaceutical company focused on medicines for genetic diseases, and its filings give detailed insight into clinical milestones, financial condition, capital structure, and corporate governance.
Current reports on Form 8-K are a key source of information for BBIO. The company uses 8-K filings to report material events such as positive Phase 3 topline results for encaleret in autosomal dominant hypocalcemia type 1 and for BBP-418 in LGMD2I/R9, quarterly business updates and financial results, and significant agreements like royalty interest purchase and sale arrangements tied to acoramidis royalties in Europe. 8-Ks also describe shareholder votes on amendments to the certificate of incorporation, stock incentive plans, and other governance matters.
Investors can also review filings that discuss BridgeBio’s financing activities, including proposed offerings of convertible senior notes and the terms, ranking, and convertibility features of such instruments, as well as transactions that monetize future royalty streams. These documents help explain how the company funds commercialization of Attruby (acoramidis) and its broader development pipeline.
On Stock Titan, BBIO filings are updated as new documents are posted to EDGAR. AI-powered summaries highlight the main points of long forms such as 8-Ks, so readers can quickly see why a filing was made, what agreements or results were disclosed, and how it may relate to BridgeBio’s clinical programs, ATTR-CM franchise, or capital structure. Users can drill down into individual filings for full legal and financial detail, including exhibits referenced in the company’s reports.
BridgeBio Pharma’s Chief Accounting Officer, Apuli Maricel, sold shares under a pre-set trading plan. On April 30, 2026, Maricel executed an open-market sale of 2,000 shares of Common Stock at $71.58 per share. After this transaction, Maricel directly holds 134,115 shares. The sale was made pursuant to a Rule 10b5-1 sales plan adopted on September 8, 2025, indicating it was pre-arranged rather than timed spontaneously.
BridgeBio Pharma, Inc. will hold its 2026 annual stockholders meeting virtually on June 22, 2026, to vote on key governance and compensation items. Stockholders of record at the close of business on April 23, 2026, when 195,806,242 common shares were outstanding, may vote.
Proposals include electing three Class I directors, advisory votes on executive pay and the frequency of future say‑on‑pay votes, ratifying Deloitte & Touche LLP as auditor for 2026, and approving an amendment to the 2021 Stock Option and Incentive Plan to add 2,000,000 reserved shares. Director Randal W. Scott will not stand for re‑election, and the board size will be reduced from 14 to 13.
The company highlights a pay‑for‑performance philosophy: in 2025, 93% of CEO pay and 88% of CFO pay were at risk via bonuses and equity, and performance stock units and a stock ownership policy were added after prior say‑on‑pay support of about 75% and investor feedback.
BridgeBio Pharma reports beneficial ownership by Neil Kumar of 9,282,982 shares of Common Stock. That ownership represents 4.6% of the class based on 195,707,702 shares outstanding as of March 31, 2026. The filing breaks the total into direct holdings, exercisable options, restricted stock units vesting within 60 days, and shares held in trusts.
The filing lists 3,903,183 options exercisable within 60 days and 71,215 RSUs vesting within 60 days, plus trust-held shares totaling 5,074,133 that give shared voting/dispositive power.
BridgeBio Pharma, Inc. director and CEO Neil Kumar reported that entities associated with him sold a total of 80,000 shares of Common Stock of BBIO in open‑market transactions on April 9–10, 2026. The trades were executed by the Kumar Haldea Family Irrevocable Trust and the Kumar Haldea Revocable Trust, where he serves as co‑trustee, at prices in the mid‑$70s per share.
The filing states these sales were made under a pre‑arranged Rule 10b5‑1 sales plan adopted on March 31, 2025, and includes a disclaimer that Kumar does not admit beneficial ownership of the trust shares beyond any pecuniary interest. After the transactions, the trusts and Kumar’s direct account together still hold several million shares.
Morgan Stanley Smith Barney LLC submitted a Form 144 notice reporting proposed sales of 120,000 shares of Common Stock (Conversion Management Incentive Units) dated 03/26/2026. The filing also lists multiple 10b5-1 sales by related trusts and an individual totaling several recent transactions, including a 28,053-share sale on 02/19/2026. Shares outstanding were 193,862,871 as of 04/09/2026.
Viking Global Investors and related entities report beneficial ownership of 11,842,434 shares of BridgeBio Pharma, Inc. common stock, representing 6.1% of the class. This percentage is based on 193,862,871 shares outstanding as of February 12, 2026. The filing is Amendment No. 11 to a Schedule 13D and is primarily being made to remove former advisory director David C. Ott as a reporting person after his March 31, 2026 retirement, after which he is no longer a beneficial owner of the reported shares. The amendment restates the current group of reporting persons, describes their control structure, and notes that, other than transactions listed in Exhibit 99.13, no additional trades have occurred since the prior amendment.
BridgeBio Pharma submitted a New Drug Application to the FDA for oral BBP-418 to treat limb-girdle muscular dystrophy type 2I/R9 (LGMD2I/R9). The filing is supported by the Phase 3 FORTIFY trial’s 12‑month interim analysis, which met all pre‑specified primary and secondary endpoints.
Interim data showed rapid, consistent treatment effects, with statistically significant and clinically meaningful improvements in ambulation and pulmonary function and a favorable safety profile. BridgeBio expects, if approved, a potential U.S. launch in late 2026 or early 2027 and notes BBP-418 could become the first approved therapy for LGMD2I/R9 and potentially any form of limb-girdle muscular dystrophy.
BridgeBio Pharma submitted a New Drug Application to the FDA for oral BBP-418 to treat limb-girdle muscular dystrophy type 2I/R9 (LGMD2I/R9). The filing is supported by the Phase 3 FORTIFY trial’s 12‑month interim analysis, which met all pre‑specified primary and secondary endpoints.
Interim data showed rapid, consistent treatment effects, with statistically significant and clinically meaningful improvements in ambulation and pulmonary function and a favorable safety profile. BridgeBio expects, if approved, a potential U.S. launch in late 2026 or early 2027 and notes BBP-418 could become the first approved therapy for LGMD2I/R9 and potentially any form of limb-girdle muscular dystrophy.
Bridgebio Pharma Inc: The Vanguard Group amended its Schedule 13G to report 0 shares of Common Stock, representing 0% ownership. The filing notes an internal realignment effective January 12, 2026 that led Vanguard subsidiaries to report holdings separately.
Trimarchi Thomas reported acquisition or exercise transactions in this Form 4 filing.
BridgeBio Pharma, Inc. reported that its President and CFO, Thomas Trimarchi, received a grant of 59,041 restricted stock units (RSUs) of common stock as equity compensation. Each RSU represents a right to receive one share of common stock. The RSUs vest as to 1/16 of the underlying shares on May 16, 2026, and 1/16 each quarter thereafter, conditioned on his continued service. Following this grant, Trimarchi directly holds 395,626 shares of BridgeBio common stock.